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private practices to collect de-identified data on patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease status. Physicians from the 
US were screened for duration of practice and patient volume and recruited from a 
large panel to be geographically representative. Eligible patient charts (> 6 biologic 
patients, > 2 biologic-suitable (and yet biologic-naïve) patients per physician judg-
ment) were randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Results: Ninety-seven physicians 
abstracted 726 eligible RA patient charts; 378(52%) patients were on their first bio-
logic and 175(24%) patients have never experienced biologic but were considered 
suitable for one. Mean age was: 1st line-52.8yrs, biologic-suitable-51.5yrs; Female: 
1st line-73%, biologic-suitable-76%. Disease severity at diagnosis and current dis-
ease severity (both per physician judgment) (mild:moderate:severe) were: 1st line 
– 6%:74%:14% and 67%:29%:3%, biologic-suitable – 11%,74%, 10% and 25%:66%:9% 
respectively. Current drug class usage differed between the two groups (1st line/
biologic-suitable): non-biological-DMARD (57%/88%), steroids (19%/36%), NSAIDs-
COX2-inhibitors (6%/10%), NSAIDs- non-COX2-inhibitors (14%/22%), and analge-
sics (11%/12%). Key lab measures were (1st line/biologic-suitable): ESR(24.2/40.0 
mm/h) and CRP(2.5mg/5.6 dl). Current ACR-scores were (1st line/biologic-suita-
ble): no response(2%/19%), ACR20(12%/36%), ACR50(18%/15%), ACR70(20%/5%), 
ACR90(26%/1%). Among patients with available data, current HAQ (1st line-0.7, 
biological-suitable-1.1), DAS28 (1st line-2.5, biological-suitable-4.1), 100mmVAS 
(1st line-2.3, biological-suitable-4.6), Swollen Joint Count (1st line-2.0, biological-
suitable-5.9) and Tender Joint Count (1st line-2.8, biological-suitable-7.0) differed 
between the patient groups. ConClusions: Compared to the patients currently 
treated with 1st line biologic, RA biologic-naïve but suitable patients (per physician 
judgment) had relatively higher disease burden. Reasons for non-initiation of bio-
logic treatment among ‘biologic-suitable’ patients warrant further investigation to 
alleviate disease burden.
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objeCtives: To compare the disease status and outcomes of patients with PsA 
receiving their first biologic in UK, Germany, France, Italy and Spain (5EU) with 
the US. Methods: A multi-country multi-center medical chart-review study of 
PsA patients was conducted among physicians (majority: rheumatologists) in 
hospitals/private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians were screened 
for duration of practice and patient volume and recruited from a large panel to 
be geographically representative in each country. Eligible PsA patient charts 
(> 3) were randomly selected from a sample of prospective patients visiting each 
center/practice during the screening period. Physicians abstracted patient diag-
nosis, treatment patterns/dynamics and patient symptomatology/disease status/
outcomes. Results: In 4Q2012, 434 physicians (5EU:337, US:97) abstracted 790 
eligible PsA patient charts (5EU:606, US:184); 674 (85%) (5EU:527, US:147) patients 
were on their first biologic (mean-age: 5EU:47.4yrs, US:47.6yrs; female: 5EU:48.6%, 
US:44.9%). Time-to-1st biologic from diagnosis (5EU:41.0months, US:27.2months) 
and time-on-current biologic (5EU:23.2months, US:36.7months) differed between 
regions. Top-2 biologic treatments observed were adalimumab (5EU:47%, US:47%) 
and etanercept (5EU:36%, US:32%). Among the top-4 reasons for biologic treatment 
initiation, ‘mechanism of action’, ‘improve signs/symptoms’, ‘positive personal 
experience’ and ‘prevention of structural damage’ were observed in both the 5EU 
and US. Key lab measures documented were: ESR (5EU:20.6mm/h, US:23.7mm/h) and 
CRP (5EU:9.4mg/dl, US:2.8mg/dl). Current disease severity per physician-judgment 
(mild:moderate:severe) was: 5EU-61%:33%:5%, US-73%:26%:1%. Among patients with 
available data, current HAQ (5EU:1.3, US:0.6), VAS provider score (5EU:3.1, US:2.6), 
VAS patient score (5EU:3.4, US:2.7) and Swollen Joint Count (5EU:2.0, US:1.7) differed 
across regions. ConClusions: Among PsA patients receiving their first biologic, 
disease severity and outcomes differed between 5EU and US, with patients in 5EU 
with relatively higher burden and poorer outcomes.
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objeCtives: To assess the patterns of disease remission among RA patients receiv-
ing their first biologic in 5-EU countries, namely, UK, Germany(DE), France(FR), 
Italy(IT) & Spain(SP). Methods: A multi-country multi-center medical chart-review 
study of RA patients was conducted among physicians (majority: rheumatologists) 
in hospitals/private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians were screened 
for practice-duration and patient-volume and recruited from a large panel to be 
geographically representative in each country. Patient charts (> = 5) were randomly 
selected within each center/practice. Physicians abstracted patient diagnosis, 
treatment patterns/dynamics and patient symptomatology/disease status (incl. 
assessment of ‘disease remission’, per physician clinical judgment). Results: In 
4Q2011, 370 physicians abstracted 2208 eligible RA patient charts (UK:410, FR:499, 
DE:404, IT:415, SP:480); patient mean-age:51yrs, female:71%; 75% and 20% were on 
1st line and 2nd line biologic respectively. Overall, 53% of patients were in remis-
sion (UK:54%, FR:56%, DE:61%, IT:41%, SP:53%). Remission-rates differed by biologic 
lines: 1st-line:53%, 2nd-line:53%, 3rd-line:46%, 4th-line:42%, 5th-line:38%. Among those 
with lab measures, results differed between those in remission vs. those who were 
not: mean ESR(mm/h): 17.0vs.32.1, mean CRP(mg/dl): 7.0vs.15.6, mean MMP3(ng/
ml): 2.8-vs-4.7, Rheumatoid Factor (% positive): 83%-vs-86% and Anti-CCP (% posi-
tive): 75%-vs-79%. Among those with data, recent (mean) disease severity scores 
regression analyses were performed to identify the contributing factors to absentee-
ism. Results: A sample of 503 patients agreed to participate, of which 488 were 
evaluable. 364 patients (74.6%) were in employment, 31 (6.4%) were unemployed and 
93 (19.1%) were out of the labor market. Among the 364 patients currently in employ-
ment, 102 (28.0%), 138 (37.9%) and 124 (34.1%) were in ACR functional class of I, II and 
III/IV, respectively. The mean HAQ scores were 0.6, 1.4 and 1.5 (p< 0.0001), and 2.9%, 
16.7% and 29.0% (p< 0.0001), respectively, had an occupational disability status. An 
overall proportion of 48.3% patients declared an RA associated work absence over the 
last year. This proportion increased from 28.4% in ACR I to 62% in ACR III/IV group, 
and from 7.8% to 31.4% (p< 0.0001), respectively, for absence > 1 month. Despite a high 
uptake of biologic agents (60.4%) among these patients, RA was active for a significant 
period of time; mean 2.2 (±3.2) months in ACR I group and 4.8 (±4.2) months in ACR 
III/IV group. Regression analyses suggested that ACR functional class and frequencies 
and duration of flares were the major factors contributing to absenteeism, far ahead 
of any other socio-economic characteristics. ConClusions: Loss of productivity due 
to RA could be further reduced through better control of disease activity.
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objeCtives: Rheumatoid arthritis is an autoimmune chronic disease which is 
associated with an increasing disability of patients and high socioeconomic bur-
den. Given the large number of economic evaluations considered by national HTAs, 
this review attempts to clarify whether biologic DMARDs cost-effectiveness and 
cost-utility results form the basis for official recommendation by national HTA 
agencies. Methods: Both older biologic anti-TNFα drugs (etanercept, infliximab 
and adalimumab) and novel bDMARDs (abatacept, tocilizumab, certolizumab, goli-
mumab and rituximab) were considered. All main HTA agencies were searched 
for published economic evaluations up to 2012. Documents were selected if they 
included cost-effectiveness or cost-utility as outcome, if they referred to at least 
one of the drugs of interest, if they were published in English and if they were not 
superseded by other analysis. PICO statements were used to define exclusion crite-
ria. Results: Of the 65 documents initially identified through the search strategy, 
20 documents were selected. The associated HTA agencies were PBAC (Australia), 
CADTH (Canada), SMC (Scotland) and NICE (England). In relation to older anti-TNFα , 
documents published by NICE were found to be the only explicitly recommending 
the drugs on the basis of obtained cost-utility results. Economic evaluations of 
novel bDMARDs published by SMC and NICE appeared to inform HTA decisions not 
to recommend abatacept and to list all other drugs conditional on price facilitation 
and following failure of rituximab. By contrast, cost-utility analysis published by 
PBAC and CADTH did not appear to influence official recommendations on novel 
biologic DMARDs. ConClusions: Cost-effectiveness and cost-utility evidence was 
not equally perceived by decison makers and did not have equal weight in defining 
the official listing of biologic DMARDs for the treatment of RA. Further research 
should therefore address methods for a greater integration between health eco-
nomic analysis and final decisions taken by National HTA agencies.
PMS91
CoSt-effeCtiveneSS analySiS of alenDronate theraPy for SeConDary 
Prevention of oSteoPorotiC fraCtureS
Moriwaki K.1, Komaba H.2, Noto S.1, Yanagisawa S.3, Takiguchi T.1, Toujo T.1, Inoue H.1, 
Fukagawa M.2, Takahashi H.E.1
1Niigata University of Health and Welfare, Niigata, Japan, 2Tokai University School of Medicine, 
Isehara, Japan, 3Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Japan
objeCtives: Although osteoporotic fractures impose a heavy financial burden on 
society as a whole, only 20% of patients with osteoporosis and in risk of fracture 
are being treated. The purpose of this study was to estimate the cost-effective-
ness of alendronate therapy for secondary prevention of osteoporotic fractures in 
Japan. Methods: A patient-level simulation model with nine health states was 
developed to predict lifetime costs and quality-adjusted life years (QALYs) of five 
years of alendronate therapy versus no preventive treatment for Japanese women 
with osteoporosis, who have a history of hip fracture. Fracture risk associated with 
age and bone mineral density (BMD) was derived from epidemiologic studies in 
Japan. We ran the model with different combinations of age (50, 60, and 70), BMD 
(T-score of −2.5 and −2.0), and BMD-independent fracture risk factors. Results: 
For patients with T-score of -2.0 having no additional risk factors, the incremental 
cost-effectiveness ratio (ICER) of alendronate was $3,023 and $7,389 per QALY gained 
for those aged 60 and 70 years, respectively. In all other situations, alendronate 
was dominant over no preventive treatment, with lifetime cost savings ranging 
from $30,849 to $1,498,961. These results were fairly robust to variations in model 
parameters. ConClusions: Alendronate therapy for secondary fracture prevention 
in Japanese women with osteoporosis provided good value for money.
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objeCtives: To assess clinical characteristics of RA patients considered suitable 
for biologic therapy (by their physicians) in comparison to those currently treated 
with 1st line biologics in the US. Methods: A medical chart-review study of RA 
patients was conducted among physicians (primarily rheumatologists) in hospitals/
